Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Dupilumab sustains lung function improvements in patients with moderate-to-severe asthma.

Papi A. et al, (2024), Respiratory medicine, 224

Dupilumab reduces exacerbations independent of changes in biomarkers in moderate-to-severe asthma.

Pavord ID. et al, (2024), The journal of allergy and clinical immunology. In practice

Effect of Individual Patient Characteristics and Treatment Choices on Reliever Medication Use in Moderate-Severe Asthma: A Poisson Analysis of Randomised Clinical Trials.

van Dijkman SC. et al, (2024), Advances in therapy, 41, 1201 - 1225

The airway epithelium: an orchestrator of inflammation, a key structural barrier and a therapeutic target in severe asthma.

Russell RJ. et al, (2024), The European respiratory journal

Type-2 inflammation: a key treatable trait associated with lung function decline in chronic airways disease

Petousi N. et al, (2024), Thorax

Biomarkers Associated with Lung Function Decline and Dupilumab Response in Patients with Asthma.

Pavord ID. et al, (2024), American journal of respiratory and critical care medicine

Pioneering a paradigm shift in asthma management: remission as a treatment goal.

Lommatzsch M. et al, (2024), The Lancet. Respiratory medicine, 12, 96 - 99

Blood eosinophils and fractional exhaled nitric oxide are prognostic and predictive biomarkers in childhood asthma.

Bacharier LB. et al, (2024), The Journal of allergy and clinical immunology

From treatable traits to GETomics in airway disease: moving towards clinical practice.

Papi A. et al, (2024), European respiratory review : an official journal of the European Respiratory Society, 33

How have we measured trial outcomes of asthma attack treatment? A systematic review.

Howell I. et al, (2024), ERJ open research, 10, 660 - 2023

Fractional exhaled nitric oxide (FeNO): the future of asthma care?

Wang K. et al, (2023), The British journal of general practice : the journal of the Royal College of General Practitioners, 73, 565 - 568

Understanding the Clinical Implications of Individual Patient Characteristics and Treatment Choice on the Risk of Exacerbation in Asthma Patients with Moderate-Severe Symptoms.

Singh D. et al, (2023), Advances in therapy, 40, 4606 - 4625

Which biologic? New findings from a real‐world study

Lavoie G. and Pavord ID., (2023), Respirology

Cluster Analyses From the Real-World NOVELTY Study: Six Clusters Across the Asthma-COPD Spectrum.

Hughes R. et al, (2023), The journal of allergy and clinical immunology. In practice, 11, 2803 - 2811

Dupilumab efficacy in high sleep disturbance management among patients with type 2 asthma.

Maspero JF. et al, (2023), Respiratory medicine, 218

European Respiratory Society Short Guidelines for the use of as-needed ICS/formoterol in mild Asthma.

Papi A. et al, (2023), The European respiratory journal

The Anti-Inflammatory Reliever (AIR) Algorithm Study: a protocol for a single-group study of an AIR stepwise approach to the treatment of adult asthma.

Bruce P. et al, (2023), ERJ open research, 9, 239 - 2023

Tezepelumab reduces exacerbations across all seasons in patients with severe, uncontrolled asthma (NAVIGATOR).

Pavord ID. et al, (2023), Ann Allergy Asthma Immunol

Dupilumab sustains efficacy in patients with moderate‐to‐severe type 2 asthma regardless of ICS dose

Pavord ID. et al, (2023), Allergy

Type 2 inflammation and biological therapies in asthma: Targeted medicine taking flight

Howell I. et al, (2023), Journal of Experimental Medicine, 220

Load More

1
2
3
4
5
6
7
...
»

Include forthcoming?